Alternative dosing for PPI therapy: Rationale and options

Reviews in Gastroenterological Disorders

Volumn 3, Issue SUPPL. 4, 2003, Pages

  Johnson, David A ^a  

^a Eastern Virginia School of Medicine   (United States)

Author keywords

Cost effectiveness; Gastric acid; Proton pump inhibitors; Ulcer

Indexed keywords

BICARBONATE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ARTICLE; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG COST; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STABILITY; ENTERIC COATED TABLET; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; HUMAN; PEPTIC ULCER; STOMACH ACID SECRETION; STOMACH PH; STRESS ULCER; SUSPENSION; TABLET DISINTEGRATION; TABLET FORMULATION; ULCER HEALING;

ANTACIDS; CAPSULES; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; TREATMENT OUTCOME;

EID: 0348162319     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Song JC, Quercia RA, Fan C, et al. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health Syst Pharm. 2001;58:689-694.
2. Zimmerman A, Walter JK, Katona B, Souney P. Alternative methods of proton pump inhibitor administration. Consult Pharm. 1997;12:990-998.
3. Sharma VK, Vasudeva R, Howden CW. A study of the effects or per-gastrostomy administration of an alkaline suspension of omeprazole on intragastric acidity. Aliment Pharmacol Ther. 1999;13:1091-1096.
4. Sharma VK. Comparison of 24 hr intragastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm. 1999;56(23 suppl 4):S18-S21.
5. Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension-a liquid formulation of lansoprzole-effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol. 1999;94:1813-1817.
6. Sharma VK, Peyton B, Spear T, et al. Oral pharmacokinetics of omeprazole and lansoprazole after single and multiple doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther. 2000;14:887-892.
7. Ferron GM, Ku S, Abell M, et al. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Am J Health Syst Pharm. 2003;60:1324-1329.
8. Quercia RA, Fan C, Liu X, Chow MSS. Stability of omeprazole in an extemporaneously prepared oral liquid. Am J Health Syst Pharm. 1997;54:1833-1836.
9. DiGiancinto JL, Bergman KL, Hoie EB, Olsen KM. Stability of liquid formulatons of lansoprazole and omeprazole stored in amber colored plastic oral syringes. ASHP Midyear Clinical Meeting. 1998;33(December):P378R.
10. Dentinger PJ, Swenson CF, Anaizi NH. Stability of pantoprazole in an extemporaneously compounded oral liquid. Am J Health Syst Pharm. 2002:59:953-956.
11. Phillips JO, Olsen KM, Rebuck JA, et al. A randomized, pharmacokinetic and pharmacodynamic cross over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol. 2001; 96:367-372.
12. Chun AHC, Shi HH, Achari R, et al. Lansoprazole: adminstration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Therapeutics. 1996;18:833-842.
13. Sostek MB, Chen YS, Skammer W, et al. Esomeprazole: nasogastric tube administration of the contents of an opened capsule suspended in water compared with oral administration in healthy volunteers. Am J Gastroenterol. 2002; 97(9):S23. Abstract 69.
14. Johnson DA, Roach AC, Carlsson AS, et al. Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages. Pharmacotherapy. 2003;23:731-734.
15. Doan TT, Wang Q, Griffin JS, et al. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am J Health System Pharm. 2001; 58:1512-1519.
16. Sostek MB, Blychert E, Karlsson A, Hulthe A. An in vitro study of the administration of esomeprazole enteric coated pellets through naso-gastric and gastrostomy tubes. Am J Gastroenterol. 2002;97(9):S23. Abstract 9.
17. White CM Kalus FS, Quercia R, et al. Delivery of esomeprazole magnesium enteric coated pellets through small caliber and standard nasogastric tubes and gastrostomy tubes in vitro. Am J Health Syst Pharm. 2002;59:2085-2088.
18. Chun AHC, Erdman K, Zhang Y, et al. Effect on the bioavailability of admixing the contents of lansoprazole capsules with selected soft foods. Clin Ther. 2000;22:231-236.
19. Chun A, Eason C, Shi H, et al. Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clin Ther. 1995;17:441-447.
20. Andersson T, Magner DJ, Patel JB, et al. Esomeprazole 40 mg capsules are bioequivalent when administered intact or as the contents mixed with applesauce. Clin Drug Invest. 2001;21:67-71.
21. Laterre PF, Horsmans Y. Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hr on intragastric pH. Crit Care Med. 2001;29:1931-1935.
22. Trepanier EF. Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. Can J Gastroenterol. 2000;14 (suppl):11D-20D.
23. Lau JYW, Sung JJY, Lee KKC, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;34:310-316.
24. Morgan D. Intravenous proton pump inhibitors in the critical care setting. Crit Care Med. 2002;30(6 suppl). S369-S372.
25. Chan EP, Goebig M, Demers RF, Katzka DA, Metz DC. Intravenous pantoprazole to prevent rebleeding after endoscopic hemostasis of bleeding ulcers: initial U.S. experience. Gastroenterology. 2003;124(4 suppl 1): A-626 Abstract W1082.
26. Taubel JJ, Sharma VK, Chiu YL, et al. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH. Aliment Pharmacol Ther. 2001;15:1807-1817.
27. Freston J, Chiu YL, Jian PW, et al. Effects on 24 hr intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am J Gastroenterol. 2001;96:2058-2065.
28. Armstrong D, Bair D, Tanser L, et al. Oral esomeprazole vs. intravenous pantoprazole-effect on intragastric pH in healthy volunteers. Can J Gastroenterol. 2003; 17: (suppl A) abstract 157.
29. Lasky MR, Metzier MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma. 1998;44:527-533.
30. Lee KKC, You JHS, Wong ICK, et al. Cost-effectiveness analysis of high dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. Gastrointest Endosc. 2003;57:160-164.
31. Enns RA, Gagnon YM, Rioux KP, Levy AR. Cost effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2003;17:225-233.
32. Vakil NM. Appropriateness of use of PPIs. Gastroenterology. 2003;124(4 suppl 1):A-626. Abstract W1082.
33. Katz PO. Ambulatory intragastric pH monitoring: clinical laboratory to clinical practice. Rev Gastroenterol Disord. 2003;3(suppl 4):S3-S9.